Boards, Advisory Committees, Professional Organizations
reviewer board, bio-protocol (2016 - Present)
Bachelor of Science, Jilin University (2007)
Doctor of Philosophy, Temple University (2012)
Current Research and Scholarly Interests
I hope you have a happy day with your research!
Nephrology (postdoc 2013-current)
Diabetes causes kidney disease in 40% of the patients, and people don`t know which gene(s) causes the differential susceptibility to kidney disease. By using modern biotechnology such as microarray, I aim to identify the genes that cause diabetic kidney disease. These genes may become biomarkers for early diagnosis or new therapeutic targets for treatments. My expertise includes primary cell isolation and flow cytometry, IHC/IF (paraffin and frozen), WB/qPCR, establishing ELISA methods, chromatography, cell culture, animals/i.v. injection/hydrodynamic injection. I have a 3-year postdoctoral fellowship from Larry L. Hillblom Foundation.
Cancer (Ph.D 2009-2013)
Late diagnosis of cancer often causes death due to metastasis. By establishing ELISA method to detect a new cancer marker, I aim to detect cancer early so that the doctors can eliminate death. This new cancer marker and ELISA method are patented or under patent application. I further studied the biological function of this cancer marker to discover a new therapeutic target.
Communication facilitator (2014-current)
A scientist needs communications to promote their research. I learned scientific communication in Stanford Leadership in Communication (workshop), and later become a facilitator in the workshop to coach beginners.
Vivek Bhalla, Department of Nephrology (2/15/2013 - 2/15/2015)
- Study of the analgesic activities, chronic toxicity and addictive potential of Jia-Yuan-Qing pill in rats EXPERIMENTAL AND THERAPEUTIC MEDICINE 2015; 9 (6): 2349-2355
- The missing link: studying the alternative TGF-ß pathway provides a unifying theory for different components of diabetic nephropathy. Diabetes 2015; 64 (6): 1898-1900
G-protein coupled receptor-associated sorting protein 1 (GASP-1), a ubiquitous tumor marker
EXPERIMENTAL AND MOLECULAR PATHOLOGY
2012; 93 (1): 111-115
Using an innovative "2-D high performance liquid electrophoresis" (2-D HPLE) technology we identified that a specific fragment of G-protein coupled receptor-associated sorting protein 1 (GASP-1) was present in the sera of breast cancer patients and was over-expressed in early and late stage breast tumors (Tuszynski, G.P. et al., 2011). In this study we further investigated the significance of GASP-1 as a tumor marker by investigating the expression GASP-1 in different kinds of tumors as well as in the sera of patients with various cancers. Over expression of GASP-1 was detected in brain, pancreatic, and breast cancers as compared to their respective normal tissues as assessed by immunohistochemical staining of tissue arrays using a "peptide specific" GASP-1 antibody. We found that across these cancers, GASP-1 was expressed approximately 10 fold more in the cancer as compared to normal tissue. The increase in GASP-1 expression was also seen in hyperplastic and inflammatory lesions of breast and pancreatic cancers as compared to normal tissue. GASP-1 was primarily expressed in the tumor epithelium of the epithelial-derived cancers and in the transformed glial cells of the brain tumors. Using a sensitive "competitive ELISA" for GASP-1, we found that sera from patients with brain, liver, breast and lung cancers expressed 4-7 fold more GASP-1 peptide than sera from normal healthy individuals. These studies identify GASP-1 as a potential new serum and tumor biomarker for several cancers and suggest that GASP-1 may be a novel target for development of cancer therapeutics.
View details for DOI 10.1016/j.yexmp.2012.03.013
View details for Web of Science ID 000305924000015
View details for PubMedID 22483848
G-protein coupled receptor-associated sorting protein 1 (GASP-1), a potential biomarker in breast cancer
EXPERIMENTAL AND MOLECULAR PATHOLOGY
2011; 91 (2): 608-613
An innovative "2-D high performance liquid electrophoresis" (2-D HPLE) technology was used to identify serum biomarkers associated with the early stage of breast cancer in addition to other more advanced stages. 2-D HPLE is a newly developed electrophoretic technology that separates 100s of serum albumin complexes on a polyvinyl membrane based on their surface charges. Association of cancer proteins or their fragments (biomarkers) with pre-existing albumin complexes in the blood of cancer patients results in altered mobility on the membrane. Using 2-D HPLE we identified that a specific fragment of G-protein coupled receptor-associated sorting protein 1 (GASP-1) was present in the sera of patients with early stage disease but absent in sera of normal patients. GASP-1 has been shown to modulate lysosomal sorting and functional down-regulation of a variety of G-protein coupled receptors in neuronal cells. However, no reports have linked GASP-1 to breast cancer pathogenesis. GASP-1 was detected in tumor extracts of 7 cases of Stage 2 and Stage 3 breast cancers, but not in adjacent normal tissue as revealed by western blot analysis using an antibody developed against a GASP-1 peptide identified by our 2-D HPLE technology. Using this antibody, we immunohistochemically detected over-expression of GASP-1 in all of 107 cases of archived ductal breast carcinoma tumor samples, while normal adjacent breast tissue from 12 cases of ductal carcinoma showed little or no staining. Additionally, all 10 cases of metastatic breast carcinoma present in lymph nodes were positive. Strong positive GASP-1 staining was observed in all tumor tissue including ductal carcinoma in situ (DCIS) and invasive ductal carcinoma. Additionally, we observed a wide spectrum of enhanced staining of premalignant ductal epithelial cells present in benign ducts and those found in atypical ductal hyperplasia (ADH). These studies identify GASP-1 as a potential new serum and tumor biomarker for breast cancer and suggest that GASP-1 may be a novel target for the development of breast cancer therapeutics.
View details for DOI 10.1016/j.yexmp.2011.06.015
View details for Web of Science ID 000295907700018
View details for PubMedID 21791203